Umbilical cord blood for cardiovascular cell therapy: From promise to fact

Santiago Roura, Josep Maria Pujal, Antoni Bayes-Genis

Research output: Contribution to journalArticleResearchpeer-review

20 Citations (Scopus)


Endothelial recovery and cell replacement are therapeutic challenges for cardiovascular medicine. Initially employed in the treatment of blood malignancies due to its high concentration of hematological precursors, umbilical cord blood (UCB) is now a non-controversial and accepted source of both hematopoietic and non-hematopoietic progenitors for a variety of emerging cell therapies in clinical trials. Here, we review the current therapeutic potential of UCB, focusing in recent evidence demonstrating the ability of UCB-derived mesenchymal stem cells to differentiate into the endothelial lineage and to develop new vasculature in vivo. © 2012 New York Academy of Sciences.
Original languageEnglish
Pages (from-to)66-70
JournalAnnals of the New York Academy of Sciences
Issue number1
Publication statusPublished - 1 Jan 2012


  • Cardiovascular diseases
  • Mesenchymal stem cell
  • Umbilical cord blood


Dive into the research topics of 'Umbilical cord blood for cardiovascular cell therapy: From promise to fact'. Together they form a unique fingerprint.

Cite this